AAV Edge System: A Suite Of Tools To Advance Gene Therapy Design And Production

Scaling adeno-associated virus (AAV) production often forces a compromise between speed and stability. The AAV Edge System utilizes stable producer cell lines to deliver genomic titers up to 6E15 vg/L within a compressed 20-week timeline. This platform integrates a high-performance, suspension-adapted clonal GMP HEK293 host with advanced payload design tools. By employing AI-designed tissue-specific promoters and proprietary sequence optimization software, the AAV Edge System potentially improves safety and increases transgene expression by up to 7-fold.

Additionally, the platform addresses common manufacturing hurdles through gene of interest (GOI) silencing, preventing toxicity without impacting final viral yield. Want to learn more? Download the brochure below to explore how these modular tools can advance your specific therapeutic design and production goals.